Collection 

Mechanisms and management of metabolic cardiovascular disease

Submission status
Open
Submission deadline

Metabolic cardiovascular disease, referring to cardiovascular disease (CVD) caused by the accumulation of metabolic risk factors, is rapidly increasing and shows a younger trend globally. Risk factors have become increasingly diverse, and are no longer limited to common metabolic abnormalities such as obesity, abnormal blood pressure, glucose and lipid metabolism. In recent years, the impact of other metabolic factors such as non-alcoholic fatty liver disease, abnormal amino acid metabolism, thyroid dysfunction, gut microbiota metabolites, immune activation and systemic inflammation has received increasing attention.

Metabolic cardiovascular disease involves multiple fields, and it is necessary to strengthen the joint management of both cardiovascular and metabolic diseases. Since co-presence of multiple metabolic risk factors is often seen in a person, the interaction of these risk factors will further increase the risk of CVD. Thus, patients with metabolic CVD should be individualized comprehensive management in clinical practice. Accordingly, drug development has constantly been updated, providing new tools and ideas for effectively controlling metabolic risk factors and cardiovascular complications. For example, new hypoglycemic drugs such as GLP-1 receptor agonists and SGLT-2 inhibitors have shown significant cardiovascular benefits in addition to their therapeutic effects on glucose metabolism.

However, the clinical management of metabolic CVD is still unsatisfactory, mainly due to the complexity of the pathogenesis, and more systematic exploration is needed to target residual risks. Developing biomarkers with state-of-the-art methods such as multi-omics analysis can empower individualized intervention through predicting future risk to tailor primary prevention better, as well as identifying disease in the earliest stage.

Therefore, this research collection aims to call for papers on the frontier of research, focusing on pathogenesis and etiology, residue risk factor exploration, risk stratification, prevention and treatment of metabolic CVD.

We welcome both clinical and basic original articles, meta-analysis and reviews, covering, but not limited to, the following topics:

  • Description of metabolic disorder profiles of metabolic CVD progress including target organ damages and diseases, especially among different subgroups such as region, age, sex, and status of co-morbidities.
  • Basic research exploring the mechanisms contributing to the pathogenesis and etiology as well as treatments of CVD.
  • Identifying novel risk factors associated with metabolic CVD as well as target organ damage, especially by using multi-omics strategy and exploring the interactions of genetic and environmental factors.
  • Building and improving the risk prediction models in both primary and secondary prevention by adding new biomarkers or adopting artificial intelligence (AI) methods.
  • Evaluation of strategy for risk factor control and metabolic CVD prevention, such as lifestyle changes, new medications and interventions. Methods including use of digital therapeutics and wearable devices are also welcome.
Submit manuscript
Manuscript editing services
3D illustration of a heart

Editors

  • Yan Zhang, MD

    Yan Zhang, MD

    Peking University First Hospital, Beijing, China

All articles have undergone npj Cardiovascular Health's standard peer review process and have been subject to all the journal’s standard policies. This includes the journal’s policy on competing interests. The Editors declare no competing interests with the submissions which they have handled through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.

If accepted for publication, an article processing charge applies (with standard waiver policy). If your institution or country has an open access agreement with Springer Nature, you may publish your article OA at no cost or in some cases with the costs partially funded (see details here).  

All Collections are open for submissions from all authors – and not by invitation only – on the condition that the manuscripts fall within the scope of the Collection and of npj Cardiovascular Health's more generally.

Manuscripts submitted to an open Collection may be considered unsuitable for inclusion, particularly if they fall outside the scope of the Collection. In such cases, the authors will be notified by the editorial office and their manuscript can be considered as a regular npj Cardiovascular Health's submission.

npj Cardiovascular Health's in-house editors reserve the right to assume responsibility for the management of a Collection at any stage.